Skip to main content
Signal8

Eocene Announces its First European Sales and Distribution Agreement to Accelerate the Commercialization of Colospan's CG-100 Device

$EOCNPress releaseNov 10, 2026, 8:00 AM ETRead the release

Eocene's subsidiary Colospan signed its first European distribution agreement for the CG-100 device, granting Hospital Line SA exclusive rights to market and sell in Greece and Cyprus. The agreement includes exclusivity and commercial targets, with a launch planned at the 17th Hellenic-Cypriot Surgical Conference, running in parallel with CG-100's ongoing U.S. pivotal study.

Key figures

Drug Name
CG-100
Us status
investigational use only; not approved for commercial use in the United States
Exclusivity territories
["Greece","Cyprus"]

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.